Gilead has also made strides in expanding beyond HCV and HIV. The big biotech acquired Kite Pharma in 2017, picking up promising CAR-T cancer drug Yescarta. While the launch of Yescarta has been slow, that was expected because of the complexities involved with administering CAR-T therapies. Over the long run, Yescarta has the potential to become another blockbuster for Gilead.